interpath-002: pembrolizumab with a neoantigen therapy in completely resected nsclc
Published 2 months ago • 42 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:22
interpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
4:22
neoantigen vaccine with pembrolizumab has clear benefit in resected melanoma
-
6:49
evoke-02: sacituzumab govitecan and pembrolizumab in first-line nsclc
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
1:13
a new standard of care for advanced lung cancer: what’s next for pembrolizumab?
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
4:11
personalized, neoantigen-directed immunotherapy in patients with advanced mss-crc, gea and nsclc
-
1:14
keynote-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
-
2:31
differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
5:00
implications for pembrolizumab in nsclc
-
4:23
keynote-407: 3-year follow-up of pembrolizumab plus chemo in nsclc
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
0:50
phase i study of tak-676 pembrolizumab following radiotherapy in late-line nsclc, tnbc and scchn
-
0:53
dr. sequist on pembrolizumab monotherapy in nonsquamous nsclc